NYSE - Delayed Quote USD

Revvity, Inc. (RVTY)

Compare
121.51 +1.28 (+1.06%)
At close: October 11 at 4:00 PM EDT
121.51 0.00 (0.00%)
After hours: October 11 at 6:00 PM EDT
Loading Chart for RVTY
DELL
  • Previous Close 120.23
  • Open 120.04
  • Bid 119.71 x 1000
  • Ask 121.36 x 1000
  • Day's Range 120.54 - 122.69
  • 52 Week Range 79.50 - 128.15
  • Volume 575,671
  • Avg. Volume 727,657
  • Market Cap (intraday) 14.987B
  • Beta (5Y Monthly) 1.05
  • PE Ratio (TTM) 75.94
  • EPS (TTM) 1.60
  • Earnings Date Nov 4, 2024
  • Forward Dividend & Yield 0.28 (0.23%)
  • Ex-Dividend Date Oct 18, 2024
  • 1y Target Est 138.34

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

www.revvity.com

11,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RVTY

View More

Performance Overview: RVTY

Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RVTY
11.38%
S&P 500
21.91%

1-Year Return

RVTY
10.69%
S&P 500
33.43%

3-Year Return

RVTY
28.04%
S&P 500
32.42%

5-Year Return

RVTY
52.71%
S&P 500
97.92%

Compare To: RVTY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RVTY

View More

Valuation Measures

Annual
As of 10/11/2024
  • Market Cap

    14.99B

  • Enterprise Value

    17.03B

  • Trailing P/E

    75.94

  • Forward P/E

    23.36

  • PEG Ratio (5yr expected)

    3.07

  • Price/Sales (ttm)

    5.55

  • Price/Book (mrq)

    1.90

  • Enterprise Value/Revenue

    6.29

  • Enterprise Value/EBITDA

    23.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.26%

  • Return on Assets (ttm)

    1.59%

  • Return on Equity (ttm)

    2.51%

  • Revenue (ttm)

    2.71B

  • Net Income Avi to Common (ttm)

    197.34M

  • Diluted EPS (ttm)

    1.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.95B

  • Total Debt/Equity (mrq)

    50.79%

  • Levered Free Cash Flow (ttm)

    585.85M

Research Analysis: RVTY

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 691.68M
Earnings 55.36M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

120.00
138.34 Average
121.51 Current
185.00 High
 

Company Insights: RVTY

Research Reports: RVTY

View More
  • Lowering target price to $128.00

    REVVITY INC has an Investment Rating of HOLD; a target price of $128.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • What does Argus have to say about RVTY?

    REVVITY INC has an Investment Rating of HOLD; a target price of $131.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • Raising target price to $131.00

    REVVITY INC has an Investment Rating of HOLD; a target price of $131.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • Raising target price to $129.00

    REVVITY INC has an Investment Rating of HOLD; a target price of $129.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     

People Also Watch